GE Healthcare Technologies Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on October 28, 2026, reporting total revenues of $5,513 million for the three months ended September 30, 2026.

Key Highlights

  • Total revenues (Q3 2026): $5,513 million, compared with $5,143 million in Q3 2025.
  • Total revenues (nine months ended September 30, 2026): $15,939 million, compared with $14,927 million in the same period of 2025.
  • Gross profit (Q3 2026): $2,224 million, up from $1,990 million in Q3 2025.
  • Product sales (Q3 2026): $3,602 million, versus $3,375 million in Q3 2025.
  • Service sales (Q3 2026): $1,911 million, versus $1,769 million in Q3 2025.
  • Shares outstanding: 452,137,831 shares of common stock as of October 21, 2026.
  • SG&A expense (Q3 2026): $1,100 million, compared with $1,045 million in Q3 2025.

GE Healthcare Third-Quarter 2026 Financial Results Overview

According to the filing, GE Healthcare Technologies Inc. (NASDAQ:GEHC) reported total revenues of $5,513 million for the three months ended September 30, 2026, compared with $5,143 million in the corresponding prior-year quarter. The company disclosed that product sales contributed $3,602 million and service sales contributed $1,911 million to the quarterly total. For the nine-month period ended September 30, 2026, the company reported total revenues of $15,939 million versus $14,927 million for the same period in 2025.

The filing reported gross profit of $2,224 million for Q3 2026, compared with $1,990 million for Q3 2025. Cost of products for the quarter was $2,373 million and cost of services was $916 million, according to the condensed consolidated statements of income. For the nine months ended September 30, 2026, cost of products totaled $6,873 million and cost of services totaled $2,685 million, the filing stated. Gross profit for the nine-month period was $6,381 million, compared with $5,987 million for the same period in 2025.

Selling, general, and administrative expense for Q3 2026 was reported at $1,100 million, versus $1,045 million in Q3 2025. Research and development expense for Q3 2026 was disclosed at $320 million. The company reported 452,137,831 shares of common stock outstanding as of October 21, 2026, with a par value of $0.01 per share. The filing notes that it contains forward-looking statements subject to the company's cautionary language, including risks related to tariffs, trade policy, macroeconomic conditions, and geopolitical factors.

What Was Disclosed

GE Healthcare Technologies Inc. filed its quarterly report covering the period ended September 30, 2026, disclosing condensed consolidated income statement data, share count, and segment and supplemental financial information, along with risk factors and management discussion sections.